CN105132544A - 用于肿瘤特征和标记物组鉴定，肿瘤分级的方法和用于癌的标记物组 - Google Patents

用于肿瘤特征和标记物组鉴定，肿瘤分级的方法和用于癌的标记物组 Download PDF

Info

Publication number
CN105132544A
CN105132544A CN201510530592.2A CN201510530592A CN105132544A CN 105132544 A CN105132544 A CN 105132544A CN 201510530592 A CN201510530592 A CN 201510530592A CN 105132544 A CN105132544 A CN 105132544A
Authority
CN
China
Prior art keywords
gene expression
cancer
tumor
marker
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510530592.2A
Other languages
English (en)
Chinese (zh)
Inventor
E·王
李�杰
邓迎海
A·Eg·伦费林克
M·D·奥康纳-麦考特
E·普里西马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Publication of CN105132544A publication Critical patent/CN105132544A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G01N33/57515—
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201510530592.2A 2009-04-16 2010-04-16 用于肿瘤特征和标记物组鉴定，肿瘤分级的方法和用于癌的标记物组 Pending CN105132544A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20288109P 2009-04-16 2009-04-16
US61/202,881 2009-04-16
CN201080020971.2A CN102421920B (zh) 2009-04-16 2010-04-16 用于肿瘤特征和标记物组鉴定,肿瘤分级的方法和用于癌的标记物组

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080020971.2A Division CN102421920B (zh) 2009-04-16 2010-04-16 用于肿瘤特征和标记物组鉴定,肿瘤分级的方法和用于癌的标记物组

Publications (1)

Publication Number Publication Date
CN105132544A true CN105132544A (zh) 2015-12-09

Family

ID=42982085

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201510530592.2A Pending CN105132544A (zh) 2009-04-16 2010-04-16 用于肿瘤特征和标记物组鉴定，肿瘤分级的方法和用于癌的标记物组
CN201510530687.4A Pending CN105200124A (zh) 2009-04-16 2010-04-16 用于肿瘤特征和标记物组鉴定，肿瘤分级的方法和用于癌的标记物组
CN201080020971.2A Expired - Fee Related CN102421920B (zh) 2009-04-16 2010-04-16 用于肿瘤特征和标记物组鉴定,肿瘤分级的方法和用于癌的标记物组

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201510530687.4A Pending CN105200124A (zh) 2009-04-16 2010-04-16 用于肿瘤特征和标记物组鉴定，肿瘤分级的方法和用于癌的标记物组
CN201080020971.2A Expired - Fee Related CN102421920B (zh) 2009-04-16 2010-04-16 用于肿瘤特征和标记物组鉴定,肿瘤分级的方法和用于癌的标记物组

Country Status (7)

Country Link
US (1) US20120040863A1 (enExample)
EP (1) EP2419533A4 (enExample)
JP (2) JP2012525818A (enExample)
CN (3) CN105132544A (enExample)
AU (1) AU2010237568A1 (enExample)
CA (1) CA2758041A1 (enExample)
WO (1) WO2010118520A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2913405B1 (en) 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
CA2829776A1 (en) * 2011-03-14 2012-09-20 National Research Council Of Canada Prognostic marker sets for prostate cancer
US12130290B2 (en) * 2016-11-29 2024-10-29 Trustees Of Tufts College Compositions and methods for diagnosing breast cancer
WO2018219342A1 (zh) * 2017-06-01 2018-12-06 立森印迹诊断技术有限公司 一种印记基因分级模型和诊断方法及其应用
CN110890128B (zh) * 2018-09-10 2024-02-09 立森印迹诊断技术（无锡）有限公司 一种用于检测皮肤肿瘤良恶性程度的分级模型及其应用
JP7352937B2 (ja) * 2019-07-19 2023-09-29 公立大学法人福島県立医科大学 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット
CN115064209B (zh) * 2022-08-17 2022-11-01 普瑞基准科技（北京）有限公司 一种恶性细胞鉴定方法及系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7955800B2 (en) * 2002-06-25 2011-06-07 Advpharma Inc. Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients
EP1730308A4 (en) * 2004-03-05 2008-10-08 Rosetta Inpharmatics Llc CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS
JP5690039B2 (ja) * 2004-06-04 2015-03-25 バイオセラノスティクス インコーポレイテッドＢｉｏｔｈｅｒａｎｏｓｔｉｃｓ，Ｉｎｃ． 腫瘍の同定
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US20100234292A1 (en) * 2007-04-16 2010-09-16 Ipsogen Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHANG HY ET AL.: "Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival", 《PNAS》 *
GLAS AM ET AL.: "Converting a breast cancer microarray signature into a high-throughput diagnostic test", 《BMC GENOMICS》 *
LAURA J. VAN "T VEER ET AL.: "Gene expression profiling predicts clinical outcome of breast cancer", 《NATURE》 *

Also Published As

Publication number Publication date
US20120040863A1 (en) 2012-02-16
WO2010118520A1 (en) 2010-10-21
CN102421920A (zh) 2012-04-18
EP2419533A1 (en) 2012-02-22
CN105200124A (zh) 2015-12-30
EP2419533A4 (en) 2014-12-31
AU2010237568A1 (en) 2011-11-17
JP2012525818A (ja) 2012-10-25
CN102421920B (zh) 2015-09-30
CA2758041A1 (en) 2010-10-21
JP2016073287A (ja) 2016-05-12

Similar Documents

Publication Publication Date Title
Ghorbanmehr et al. miR‐21‐5p, miR‐141‐3p, and miR‐205‐5p levels in urine—promising biomarkers for the identification of prostate and bladder cancer
Li et al. Identification of a five‐lncRNA signature for predicting the risk of tumor recurrence in patients with breast cancer
Riester et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples
Font et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer
Lin et al. Molecular classification and prediction in gastric cancer
Velmahos et al. Using deep learning to identify bladder cancers with FGFR‐activating mutations from histology images
Alsaleem et al. A novel prognostic two-gene signature for triple negative breast cancer
Herrgott et al. Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas
JP2021521536A (ja) 生体試料の多検体アッセイのための機械学習実装
AU2019250606B2 (en) Improved classification and prognosis of prostate cancer
CN102421920B (zh) 用于肿瘤特征和标记物组鉴定,肿瘤分级的方法和用于癌的标记物组
Wang et al. Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers
CN103733065A (zh) 用于癌症的分子诊断试验
Liu et al. Identification and validation of gene module associated with lung cancer through coexpression network analysis
US20090221522A1 (en) Methods to correct gene set expression profiles to drug sensitivity
CN108513587A (zh) 对转移性疾病具有预测性的基因标签
Hamid et al. Exosomal liquid biopsy in prostate cancer: a systematic review of biomarkers for diagnosis, prognosis, and treatment response
Wang et al. A robust blood gene expression-based prognostic model for castration-resistant prostate cancer
Sun et al. Genomic instability-associated lncRNA signature predicts prognosis and distinct immune landscape in gastric cancer
Qiao et al. Using machine learning method to identify MYLK as a novel marker to predict biochemical recurrence in prostate cancer
Zhou et al. Identification of small nucleolar RNA SNORD60 as a potential biomarker and its clinical significance in lung adenocarcinoma
US20170183738A1 (en) Process, Apparatus or System and Kit for Classification of Tumor Samples of Unknown and/or Uncertain Origin and Use of Genes of the Group of Biomarkers
Song et al. Identification of an inflammatory response signature associated with prognostic stratification and drug sensitivity in lung adenocarcinoma
CN114507717A (zh) 一种联合多个mRNA预测胆管癌复发的方法及其应用
US20130260384A1 (en) Method for determining cancer prognosis and prediction with cancer stem cell associated genes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151209